Form 4: Bionano Genomics Director Acquires 30,000 Stock Options
SEC Form 4 Filing
Director David L. Barker acquired 30,000 stock options in Bionano Genomics, Inc. on June 18, 2024.
Summary
- David L. Barker, a director of Bionano Genomics, Inc., acquired 30,000 stock options on June 18, 2024.
- The exercise price of these options is $0.7752.
- The options vest in equal monthly installments over 12 months, with full vesting upon the company's next annual stockholder meeting or a change of control.
- The options expire on June 18, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The acquisition of stock options by a director could be seen as a positive sign by shareholders, indicating confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date of the transaction: acquisition of 30,000 stock options. |
| 06/18/2034 | Expiration date of the stock options. |
Keywords
Bionano Genomics, Stock Options, Director, Form 4, Beneficial Ownership, Barker, BNGO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.